Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked hard but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past few shares of mine. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire job interview that I came away with an inadequate viewpoint of the company.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the know-how as well as associated intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) and the first brand new drug application approval ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it’s this individual remedy and a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on the website of its (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of my interest in this organization. Judging with the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a traditional battleground, or some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *